Search research articles
Contact Us
Filters
Showing results (1-10 of 139) with videos related to
Page
of 14
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
August 1, 1994
[Value of neoadjuvant radiochemotherapy in undifferentiated soft tissue sarcomas]
M Stuschke
Der Urologe. Ausg. A
|
December 20, 2008
[Radiotherapy of lymph node metastases]
M Stuschke
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 1, 1989
A direct method for estimating the alpha/beta ratio from quantitative dose-response data
M Stuschke
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
July 7, 1999
[Accelerated hyperfractionated compared with conventional radiotherapy in limited small-cell lung carcinoma, with concurrent chemotherapy]
M Stuschke
Biochimica Et Biophysica Acta
|
June 30, 1985
Insulin effect on translational diffusion of lipids and proteins in the plasma membrane of isolated rat hepatocytes
M Stuschke, H Bojar
Lung Cancer (Amsterdam, Netherlands)
|
November 13, 2003
Prophylactic cranial irradiation as a component of intensified initial treatment of locally advanced non-small cell lung cancer
M Stuschke, C Pöttgen
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 27, 1997
[Multimodal therapy or surgery alone in adenocarcinoma of the esophagus?]
M Stuschke, R Sauer
International Journal of Radiation Biology
|
February 17, 1998
Repair of ionizing radiation induced DNA double-strand breaks (dsb) at the c-myc locus in comparison to the overall genome
A Sak, M Stuschke
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 24, 1998
Hyperfractionation: where do we stand?
M Stuschke, H Thames
Der Urologe. Ausg. A
|
June 3, 2021
[Elective radiotherapy of pelvic lymph nodes in high-risk prostate cancer? : Evaluation of the relationship between the relative risk reduction of PSA (prostate-specific antigen) relapse within 5 years and absolute survival benefit]
M Stuschke, B Hadaschik
Page
of 14
Search research articles
Search
Showing results (1-10 of 139) with videos related to
Sort By:
Page
of 14
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
August 1, 1994
[Value of neoadjuvant radiochemotherapy in undifferentiated soft tissue sarcomas]
M Stuschke
Der Urologe. Ausg. A
|
December 20, 2008
[Radiotherapy of lymph node metastases]
M Stuschke
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 1, 1989
A direct method for estimating the alpha/beta ratio from quantitative dose-response data
M Stuschke
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
July 7, 1999
[Accelerated hyperfractionated compared with conventional radiotherapy in limited small-cell lung carcinoma, with concurrent chemotherapy]
M Stuschke
Biochimica Et Biophysica Acta
|
June 30, 1985
Insulin effect on translational diffusion of lipids and proteins in the plasma membrane of isolated rat hepatocytes
M Stuschke, H Bojar
Lung Cancer (Amsterdam, Netherlands)
|
November 13, 2003
Prophylactic cranial irradiation as a component of intensified initial treatment of locally advanced non-small cell lung cancer
M Stuschke, C Pöttgen
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 27, 1997
[Multimodal therapy or surgery alone in adenocarcinoma of the esophagus?]
M Stuschke, R Sauer
International Journal of Radiation Biology
|
February 17, 1998
Repair of ionizing radiation induced DNA double-strand breaks (dsb) at the c-myc locus in comparison to the overall genome
A Sak, M Stuschke
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 24, 1998
Hyperfractionation: where do we stand?
M Stuschke, H Thames
Der Urologe. Ausg. A
|
June 3, 2021
[Elective radiotherapy of pelvic lymph nodes in high-risk prostate cancer? : Evaluation of the relationship between the relative risk reduction of PSA (prostate-specific antigen) relapse within 5 years and absolute survival benefit]
M Stuschke, B Hadaschik
Page
of 14